Eton Pharmaceuticals (ETON)
(Delayed Data from NSDQ)
$18.34 USD
-0.12 (-0.65%)
Updated Sep 19, 2025 03:59 PM ET
After-Market: $18.29 -0.05 (-0.27%) 7:58 PM ET
5-Strong Sell of 5 5
F Value A Growth D Momentum C VGM
Fundamental Charts
About Return on Equity (TTM)
Eton Pharmaceuticals, Inc.'s return on equity, or ROE, is -0.73% compared to the ROE of the Medical - Biomedical and Genetics industry of -66.95%. While this shows that ETON has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
ETON 18.34 -0.12(-0.65%)
Will ETON be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ETON based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ETON
Eton Pharmaceuticals, Inc. (ETON) Reports Q2 Loss, Tops Revenue Estimates
Eton Pharmaceuticals, Inc. (ETON) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
ETON: What are Zacks experts saying now?
Zacks Private Portfolio Services
Eton Pharmaceuticals (ETON) Upgraded to Buy: Here's Why
Eton Pharmaceuticals (ETON) Is a Great Choice for 'Trend' Investors, Here's Why
Eton Pharmaceuticals, Inc. (ETON) Q1 Earnings Lag Estimates
Other News for ETON
MACD Bullish Signal Line Cross appears for ETON after 0.65% move
Is ETON coiling for a breakout? Bollinger Band Squeeze shows up after gaining 4.41%
Bollinger Band Squeeze appears for ETON after 0.68% move
New Uptrend appears for ETON after 1.24% move
ETON Hosts Virtual Meeting on September 25